Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Deferoxamine Intradermal Delivery Patch for Treatment of a Beta-Thalassemia Wound.

Deferoxamine Intradermal Delivery Patch for Treatment of a Beta-Thalassemia Wound. Annals of surgery open : perspectives of surgical history, education, and clinical approaches Perrault, D., Chattopadhyay, A., Sivaraj, D., Wan, D., Chen, K., Gurtner, G., Sen, S. 2024; 5 (1): e372

Abstract

In this study, we present the first-in-human use of topical deferoxamine (DFO) in the treatment of a beta-thalassemia wound. We elected to use DFO on a patient that suffered from a chronic nonhealing wound in the setting of beta-thalassemia. Despite approximately 55 weeks of marginal improvement in healing, this patient's wound healed completely after 21 weeks of treatment with DFO. We believe that DFO has the potential to accelerate healing in beta-thalassemia wounds through iron chelation.

View details for DOI 10.1097/AS9.0000000000000372

View details for PubMedID 38883943

View details for PubMedCentralID PMC11175915